超越二进制:来自跨性别病例系列的临床流行病学见解
Vibhu Mendiratta1, Sampurna Dash1
1Department of Dermatology and STD, Lady Hardinge Medical College, New Delhi, India.
Indian journal of sexually transmitted diseases and AIDS
|December 22, 2025
概括
变性人面临性传播感染的更高风险,原因包括早期的性行为. 解决社会经济障碍和改善后续护理对于改善这个服务不足的人群的健康结果至关重要.
科学领域:
- 医学研究 医学研究
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 变性人 (TG) 经历了独特的医疗保健挑战,对性传播感染 (STIs) 的脆弱性增加.
- 了解TG患者的特定临床流行病学特征对于有针对性的医疗干预至关重要.
- 印度北部的Suraksha诊所为包括TG个体在内的多元患者提供服务.
研究的目的:
- 评估印度北部一家三级医院跨性别患者的临床流行病学概况.
- 为了确定与这一群体中性传播感染相关的关键风险因素.
- 评估跨性别患者面临的医疗保健准入和后续挑战.
主要方法:
- 采用了一个案例系列设计.
- 从五名参加Suraksha诊所的跨性别患者收集了数据.
- 收集的信息包括患者的人口统计,性史,物质使用和诊断的感染.
主要成果:
- 确定的关键风险因素包括早期的性行为,受教育程度有限和不一致的物质使用.
- 确诊的感染包括梅毒,生殖器和门疹.
- 一个重大挑战是随访的高失踪率,60%的患者没有完成他们的护理.
结论:
- 这个群体中的跨性别者呈现出与社会经济和教育因素相关的特定STI个人资料.
- 尽管获得医疗保健,但患者保留仍然是一个关键问题.
- 建议积极监测,以及全面的心理和医疗支持,以克服障碍并改善跨性别患者的健康结果.
关键词:
临床-流行病学资料 临床-流行病学资料性传播感染性传播感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性跨性别者健康问题更多相关视频
相关概念视频
Sexually Transmitted Infections
858
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
858
Bias in Epidemiological Studies
1.2K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.2K
Prevalence and Incidence
1.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.5K
Case Studies
13.2K
There are many research methods available to psychologists in their efforts to understand, describe, and explain behavior and the cognitive and biological processes that underlie it.
13.2K
Confounding in Epidemiological Studies
554
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This...
554
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K


